Dazodalibep not checked
Amgen · VIB4920 · MEDI4920
FollowEvery change as it happens, and a Monday email
Trials
2 active
8 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Sjögren's Syndrome (SS), Sjögren's Syndrome
- Main trialPhase 3
- “Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1. To evaluate the effect of dazodalibep on patient-reported outcomes (PROs) in participants with SS. 2. To evaluate the effect of dazodalibep on measures of systemic activity, PROs, and salivary flow in participants with SS 3. To evaluate the safety and tolerability of multiple doses of dazodalibep in participants with SS”In the company’s words, NCT06245408 on ClinicalTrials.gov
- Other names
- VIB4920 · MEDI4920 · AMG 611
Other drugs for Sjögren's Syndrome (SS)
- DeucravacitinibBristol Myers Squibb · Phase 3
- NipocalimabJohnson & Johnson (Janssen) · Phase 3
- TelitaciceptVor Biopharma · Phase 3
- IanalumabNovartis · Phase 3
- RhPRG4Lubris Bio Pty Ltd · Phase 2
- IBI355Innovent · Phase 2
Coming up1
- 11 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 22 Oct 2026 | A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State | |
| Phase 3Recruiting | 11 Dec 2029 | A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | |
| Phase 3Completed | 23 Jul 2026 | A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity | |
| Phase 2Completed | 28 Dec 2021 | A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis | |
| Phase 2Withdrawn | Dec 2021 | Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor | |
| Phase 2Completed | 18 Jul 2022 | A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant | |
| Phase 2Completed | 1 Sep 2022 | A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome | |
| Phase 1Completed | 21 May 2018 | A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026